News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
283,525 Results
Type
Article (14583)
Company Profile (104)
Press Release (268838)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (92230)
Career Advice (543)
Deals (16197)
Drug Delivery (67)
Drug Development (38936)
Employer Resources (52)
FDA (6711)
Job Trends (6681)
News (157608)
Policy (14482)
Tag
Academia (480)
Accelerated approval (3)
Adcomms (6)
Allergies (44)
Alliances (23817)
ALS (47)
Alzheimer's disease (466)
Antibody-drug conjugate (ADC) (57)
Approvals (6765)
Artificial intelligence (131)
Autoimmune disease (10)
Automation (7)
Bankruptcy (156)
Best Places to Work (4851)
BIOSECURE Act (9)
Biosimilars (61)
Biotechnology (42)
Bladder cancer (44)
Brain cancer (18)
Breast cancer (128)
Cancer (970)
Cardiovascular disease (95)
Career advice (468)
Career pathing (12)
CAR-T (40)
Cell therapy (130)
Cervical cancer (9)
Clinical research (33170)
Collaboration (438)
Compensation (290)
Complete response letters (17)
COVID-19 (800)
CRISPR (24)
C-suite (143)
Cystic fibrosis (44)
Data (1050)
Denatured (15)
Depression (15)
Diabetes (118)
Diagnostics (1593)
Digital health (5)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (63)
Drug pricing (71)
Drug shortages (12)
Duchenne muscular dystrophy (56)
Earnings (35999)
Editorial (14)
Employer branding (5)
Employer resources (45)
Events (41028)
Executive appointments (444)
FDA (7359)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (271)
Gene editing (48)
Generative AI (9)
Gene therapy (128)
GLP-1 (371)
Government (1356)
Grass and pollen (3)
Guidances (103)
Healthcare (4150)
Huntington's disease (6)
IgA nephropathy (14)
Immunology and inflammation (47)
Indications (15)
Infectious disease (847)
Inflammatory bowel disease (65)
Inflation Reduction Act (6)
Influenza (20)
Intellectual property (52)
Interviews (73)
IPO (6421)
IRA (29)
Job creations (2144)
Job search strategy (424)
Kidney cancer (7)
Labor market (24)
Layoffs (200)
Leadership (4)
Legal (3491)
Liver cancer (23)
Lung cancer (131)
Lymphoma (78)
Machine learning (5)
Management (17)
Manufacturing (188)
MASH (44)
Medical device (1927)
Medtech (1929)
Mergers & acquisitions (10074)
Metabolic disorders (329)
Multiple sclerosis (40)
NASH (14)
Neurodegenerative disease (29)
Neuropsychiatric disorders (9)
Neuroscience (720)
NextGen: Class of 2025 (1792)
Non-profit (669)
Now hiring (12)
Obesity (170)
Opinion (123)
Ovarian cancer (35)
Pain (65)
Pancreatic cancer (36)
Parkinson's disease (63)
Partnered (8)
Patents (138)
Patient recruitment (37)
Peanut (15)
People (29452)
Pharmaceutical (66)
Pharmacy benefit managers (13)
Phase I (8893)
Phase II (14122)
Phase III (12478)
Pipeline (767)
Policy (76)
Postmarket research (1430)
Preclinical (3498)
Press Release (25)
Prostate cancer (63)
Psychedelics (10)
Radiopharmaceuticals (136)
Rare diseases (203)
Real estate (2702)
Recruiting (18)
Regulatory (10628)
Reports (22)
Research institute (600)
Resumes & cover letters (72)
Rett syndrome (2)
RNA editing (2)
RSV (11)
Schizophrenia (49)
Series A (44)
Series B (22)
Service/supplier (4)
Sickle cell disease (38)
Special edition (11)
Spinal muscular atrophy (78)
Sponsored (8)
Startups (1672)
State (2)
Stomach cancer (4)
Supply chain (36)
Tariffs (39)
The Weekly (30)
Vaccines (190)
Venture capitalists (15)
Weight loss (106)
Women's health (9)
Worklife (4)
Date
Today (57)
Last 7 days (503)
Last 30 days (1586)
Last 365 days (15288)
2025 (5887)
2024 (15797)
2023 (15839)
2022 (21100)
2021 (21624)
2020 (20269)
2019 (15926)
2018 (12430)
2017 (14780)
2016 (13709)
2015 (15980)
2014 (12795)
2013 (10820)
2012 (11667)
2011 (12220)
2010 (11142)
Location
Africa (346)
Alabama (17)
Alaska (1)
Arizona (61)
Arkansas (3)
Asia (21206)
Australia (2741)
California (2813)
Canada (1124)
China (289)
Colorado (128)
Connecticut (148)
Delaware (108)
Europe (41726)
Florida (473)
Georgia (65)
Idaho (9)
Illinois (281)
India (17)
Indiana (168)
Iowa (4)
Japan (117)
Kansas (60)
Kentucky (13)
Louisiana (3)
Maine (3)
Maryland (346)
Massachusetts (2233)
Michigan (57)
Minnesota (119)
Missouri (28)
Montana (8)
Nebraska (8)
Nevada (16)
New Hampshire (8)
New Jersey (992)
New Mexico (7)
New York (737)
North Carolina (448)
North Dakota (2)
Northern California (1207)
Ohio (71)
Oklahoma (4)
Oregon (18)
Pennsylvania (632)
Puerto Rico (8)
Rhode Island (13)
South America (549)
South Carolina (4)
Southern California (1170)
Tennessee (43)
Texas (361)
United States (10605)
Utah (47)
Virginia (95)
Washington D.C. (34)
Washington State (193)
Wisconsin (43)
283,525 Results for "x4 pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
X4 Pharmaceuticals Announces Reverse Stock Split
April 24, 2025
·
6 min read
Press Releases
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
May 1, 2025
·
15 min read
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 23, 2025
April 24, 2025
·
1 min read
Press Releases
X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025
April 24, 2025
·
1 min read
Layoffs
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient population with chronic neutropenia.
February 6, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 25, 2025
·
18 min read
Deals
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 3, 2024
X4 Pharmaceuticals today announced that, effective on May 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc.
June 3, 2024
·
1 min read
Press Releases
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2025
February 4, 2025
·
1 min read
Press Releases
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia
February 6, 2025
·
6 min read
Press Releases
X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025
March 12, 2025
·
1 min read
1 of 28,353
Next
